Modality
Nanobody
MOA
BiTE
Target
SGLT2
Pathway
Incretin
FL
Development Pipeline
Preclinical
~Jun 2010
→ ~Sep 2011
Phase 1
~Dec 2011
→ ~Mar 2013
Phase 2
~Jun 2013
→ ~Sep 2014
Phase 3
~Dec 2014
→ ~Mar 2016
NDA/BLA
~Jun 2016
→ ~Sep 2017
Approved
Dec 2017
→ Apr 2027
ApprovedCurrent
NCT05944607
903 pts·FL
2017-12→2027-04·Completed
NCT07127710
848 pts·FL
2022-07→TBD·Terminated
1,751 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-04-101.0y awayPh3 Readout· FL
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Approved
Complet…
Approved
Termina…
Catalysts
Ph3 Readout
2027-04-10 · 1.0y away
FL
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05944607 | Approved | FL | Completed | 903 | UPDRS |
| NCT07127710 | Approved | FL | Terminated | 848 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 |